Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk says Catalent buyout to close soon
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory conditions to buy the U.
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
(Bloomberg) --
Novo
Nordisk
A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal. The parties are free to close the ...
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent
Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
20m
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
1d
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Indiana Daily Student
17h
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...
2d
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...
FiercePharma
2d
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...
JD Supra
3d
Novo Nordisk Faces an Increasing Number of Lawsuits Alleging Harm Caused By Wegovy
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...
9d
Novo Nordisk to cut US list prices of two insulin products by more than 70%
Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...
2d
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...
Business Insider
2d
Novo Nordisk’s Ozempic® Gains EMA Positive Opinion for Kidney Disease Risk Reduction
Pick the best stocks and maximize your portfolio:
Novo
Nordisk
( (NVO)) has provided an update.
Novo
Nordisk
announced that the European Medicines Agency’s Committee for Medicinal Products for ...
FierceBiotech
2d
Evotec, Novo Nordisk's drug discovery accelerator debuts first 3 projects, adds 5 partners
LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...
3d
on MSN
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Catalent
United States
European Medicines Agency
Massachusetts
Feedback